Le Lézard
Classified in: Science and technology
Subjects: Conference, Trade Show, Webcast

Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O'Connor will be presenting at two upcoming investor conferences:

Mr. O'Connor will host one-on-one meetings throughout the day at both events. Live webcasts of the Company's presentations, along with the accompanying slide presentations, will be available on the Investors page of the Simulations Plus website; the webcast replays will be available for 90 days. For more information about the conferences or to schedule a one-on-one meeting with Simulations Plus, please contact Hayden IR at [email protected].

About Simulations Plus, Inc.

Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries Cognigen, DILIsym Services, and Lixoft, we offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.


These press releases may also interest you

at 03:34
FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:30
Crossover Markets Reports $3.15 Billion in Q1 Volumes
Crossover Markets Group, Inc., a digital asset technology firm focused on meeting the unique liquidity requirements of institutions, today announced several key performance indicators from Q1 trading on its flagship digital assets platform CROSSx....

at 03:20
Salesforce Unveils Zero Copy Partner Network, an Ecosystem Committed to Secure, Bidirectional Zero Copy Integration with Salesforce Data Cloud
Salesforce today announced the Salesforce Zero Copy Partner Network, a global ecosystem of technology and solution providers building secure, bidirectional zero copy integrations with Salesforce Data Cloud so that data can be actioned across the...

at 03:15
Arbolus Appoints Former EY Managing Partner Steve Martin as Chair, Setting Stage for 2024 Growth Round
Arbolus, an expert network platform, announces the appointment of Steve Martin, former EY Managing Partner, as Chair of the board, signaling a pivotal moment for the company as it embarks on an ambitious growth trajectory. Drawing from over thirty...

at 03:09
Sungrow Released Annual Report 2023: Operating Revenue Witnessed A Robust Growth of 79.5%
Sungrow, the global leading PV inverter and energy storage system provider, released its annual report 2023 recently. The company attained unprecedented revenues and profits, fueled by robust demand across diverse global markets....

at 03:05
New CPS Protection Platform: TXOne Networks Presents SageOne in Hannover
TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man...

More news about Science and technology...


News published on and distributed by: